Edge Rewrite
everything Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a40b67fc2991b965

Jump to content

Dominik Thor

Add links
From Wikipedia, the free encyclopedia

Dominik Thor
EducationUniversity of Florida; University of Vienna
OccupationsProfessor, author, pharmacist, academic
Known forPharmaceutical sciences, biomaterials, regenerative medicine, longevity science
TitlePresident of the Geneva College of Longevity Science

Dominik Thor is a professor of pharmacy, pharmaceutical scientist, and academic administrator whose work has included regenerative medicine, pharmaceutical sciences and longevity science.[1][non-primary source needed] He is president of the Geneva College of Longevity Science (GCLS) in Geneva, Switzerland, and is academically affiliated with the Carol Davila University of Medicine and Pharmacy in Bucharest.[2][non-primary source needed]

His scientific work has included cellular regeneration, hypoxia-inducible factor 1-alpha (HIF-1α), skin and hair biology,[3] and the development of educational and clinical frameworks for longevity medicine.[4] His more recent academic work has addressed physician education, evidence standards, clinical governance and the development of longevity medicine as an emerging interdisciplinary field.

Education

[edit]

Thor studied pharmaceutical sciences with a focus on pharmaceutical chemistry at the University of Florida, where he received a Master of Science degree. He subsequently completed doctoral studies in economics at the Vienna University of Economics and Business.[5][non-primary source needed] His academic background in pharmaceutical sciences and economics subsequently informed work at the intersection of biomedical research, biotechnology, healthcare education and entrepreneurship.[6][AI-generated source?][promotion?]

Career

[edit]

Thor's biomedical work has focused on regenerative medicine and cellular processes associated with ageing, including HIF-1α-related mechanisms and their potential application in skin and hair regeneration.[3] In 2023, he was first author of a blinded clinical study in the Journal of Clinical Medicine examining a HIF-related hair-restoration technology.[3] He has also been named as an inventor on patent families relating to regenerative and dermatological applications. A United States patent for a topical formulation for use in alopecia, assigned to Tomorrowlabs GmbH,[7] lists Thor and Dominik Duscher as inventors; the corresponding European patent was granted in 2024.[8][9]

In 2016, Thor co-founded the biotechnology company Tomorrowlabs with physician-scientist Dominik Duscher [de].[10] The company developed applications based on research into cellular regeneration and ageing biology. Handelsblatt profiled Tomorrowlabs and its founders in 2020 and subsequently reported on the company's commercial expansion through Douglas and its planned entry into the United States.[11][promotion?]

Thor's work subsequently expanded from regenerative medicine into longevity science, including the translation of research on ageing into preventive healthcare, medical education and clinical practice.[4] As president of the Geneva College of Longevity Science, he has been involved in the development of postgraduate and continuing education in healthy ageing and longevity medicine.[4]

Thor has also commented publicly on the convergence of ageing biology, regenerative medicine and aesthetic medicine. In a 2026 Forbes article examining the integration of longevity science into aesthetic medicine, he discussed cellular mechanisms of ageing, the potential role of aesthetic medicine as an entry point into longevity-oriented care, and the need for stronger biomarkers, clinical validation and scientific rigor in the emerging field.[12]

Selected publications

[edit]
  • Pagani, Andrea; Thor, Dominik; Panayi, Adriana C.; et al. (21 March 2025). "Iron Chelators in the Management of Autoimmune-Induced Alopecia: A Focus on Hypoxia-Inducible Factor 1 Modulation and Hair Restoration". Journal of Clinical Medicine. 14 2133. doi:10.3390/jcm14072133.
  • Yu, Danyang; Zeng, Xinyi; Barzilai, David; Thor, Dominik; Lyu, Yu-Xuan (1 July 2025). "Bridging expectations and science: a roadmap for the future of longevity interventions". Biogerontology. 26 138. doi:10.1007/s10522-025-10278-z.
  • Pagani, Andrea; Addor, Guénolé; Axmann, Guido; et al. (2026). "Toward responsible longevity medicine: Swiss framework for healthy longevity medicine clinics". Longevity. 6 (1) 2583907. Informa. doi:10.1080/30653495.2025.2583907. eISSN 3065-3495.
  • Spiru, Luiza; Thor, Dominik; Marzan, Mircea-Dan (17 March 2026). "Perspective Chapter: Alzheimer's Disease in the Era of Longevity Medicine – From Early Diagnostics to Integrated Preventive and Therapeutic Strategies". Alzheimer's Disease - Diagnostics, Pathogenesis, and Treatment. IntechOpen. doi:10.5772/intechopen.1014900. ISBN 978-1-80631-300-6.[predatory publication]

References

[edit]
  1. ↑ "Next Generation Medicine". Next Generation Medicine. Retrieved 20 September 2026.
  2. ↑ "Interview with Dr. Dominik Thor - Scientific Advisor at MOLEQLAR". MOLEQLAR (Interview). Retrieved 20 September 2026.
  3. 1 2 3 Thor, Dominik; Pagani, Andrea; Bukowiecki, Julia; et al. (6 January 2023). "A Novel Hair Restoration Technology Counteracts Androgenic Hair Loss and Promotes Hair Growth in A Blinded Clinical Trial". Journal of Clinical Medicine. 12 (2): 470. doi:10.3390/jcm12020470. ISSN 2077-0383. Archived from the original on 11 November 2025.
  4. 1 2 3 Thor, Dominik; Barzilai, David; Lyu, Yu-Xuan; Spiru, Luiza (14 December 2025). "From sick care to healthspan: educating the longevity physician for health maintenance and health promotion". Biogerontology. 27 (1): 22. doi:10.1007/s10522-025-10371-3. ISSN 1573-6768. PMC 12702796. PMID 41391057.
  5. ↑ "Dominik Thor". Live Forever Club. Archived from the original on 17 September 2026.
  6. ↑ Garth, Eleanor (12 June 2024). "'There is a need for academic education in the longevity field'". Longevity.Technology (Interview). First Longevity Ltd. Retrieved 20 September 2026.
  7. ↑ "Dominik Thor Inventions, Patents and Patent Applications - Justia Patents Search". patents.justia.com. Retrieved 20 September 2026.
  8. ↑ US11969417B2, Thor, Dominik & DUSCHER, Dominik, "Topical formulation for use in alopecia", issued 30 April 2024
  9. ↑ EP3549638A3, DUSCHER, Dominik & THOR, Dominik, "Pharmaceutical composition for use in treating an age-associated condition", issued 4 December 2019
  10. ↑ Höpner, Axel; Tuma, Thomas (10 February 2020). "Wie das Beauty-Start-up Tomorrowlabs den Markt erobert". Handelsblatt (in German). Retrieved 20 September 2026.
  11. ↑ Höpner, Axel (13 March 2021). "Tomorrowlabs-News: Das Beauty-Start-up geht in die USA". Handelsblatt (in German). Retrieved 20 September 2026.
  12. ↑ Patalon, Tal. "Aesthetic Medicine Embraces Longevity Science To Cultivate Beauty From Within". Forbes. Archived from the original on 24 July 2026. Retrieved 20 September 2026.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Dominik_Thor&oldid=1376227976"